Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $33

Benzinga · 5d ago
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $30 to $33.